- Conditions
- Non-muscle-invasive Bladder Cancer
- Interventions
- PLZ4-coated paclitaxel-loaded micelles (PPM)
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 196
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8
- Interventions
- Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Magnetic Resonance Imaging, Mitomycin, Pembrolizumab, Questionnaire Administration, Radiation Therapy
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 145
- States / cities
- Tucson, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 103 more
- Conditions
- Superficial Bladder Cancer
- Interventions
- Chemophase
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Anaheim, California • La Mesa, California + 2 more
- Conditions
- Bladder Cancer
- Interventions
- eflornithine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2007
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Anaheim, California + 49 more
- Conditions
- Nonmuscle-invasive Bladder Cancer
- Interventions
- T3011
- Biological
- Lead sponsor
- ImmVira Pharma Co. Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 9
- States / cities
- Queen Creek, Arizona • Los Angeles, California • Orlando, Florida + 6 more
- Conditions
- Non-muscle-invasive Bladder Cancer
- Interventions
- STM-416
- Drug
- Lead sponsor
- SURGE Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 20
- States / cities
- Mesa, Arizona • Tucson, Arizona • Little Rock, Arkansas + 16 more
- Conditions
- Bladder Cancer
- Interventions
- paclitaxel
- Drug
- Lead sponsor
- Mary Babb Randolph Cancer Center at West Virginia University Hospitals
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2004
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
- Interventions
- Vepugratinib, Pembrolizumab, enfortumab vedotin, Trastuzumab Deruxtecan, Midazolam, Digoxin, Rosuvastatin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 677 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 41
- States / cities
- Tucson, Arizona • Duarte, California • Los Angeles, California + 29 more
- Conditions
- Bladder Cancer
- Interventions
- ADXBLADDER
- Diagnostic Test
- Lead sponsor
- Arquer Diagnostics Ltd
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 13
- States / cities
- Denver, Colorado • Daytona Beach, Florida • Jeffersonville, Indiana + 10 more
- Conditions
- Bladder Cancer
- Interventions
- Intravenous MK-3475/ Intravesical BCG
- Drug
- Lead sponsor
- Southern Illinois University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 3
- States / cities
- Springfield, Illinois • Detroit, Michigan
- Conditions
- Bladder Cancer, Urinary Bladder Neoplasms
- Interventions
- MK-3120
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- Bakersfield, California • New Brunswick, New Jersey • Myrtle Beach, South Carolina + 1 more
- Conditions
- Bladder Cancer
- Interventions
- Apaziquone, Placebo
- Drug · Other
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Urothelial Carcinoma, Muscle Invasive Bladder Urothelial Carcinoma, Non-Muscle Invasive Bladder Urothelial Carcinoma
- Interventions
- Not listed
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Omaha, Nebraska • Philadelphia, Pennsylvania
- Conditions
- Non-Muscle Invasive Bladder Cancer
- Interventions
- Sacituzumab tirumotecan, Rescue medication, Supportive care measures
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 4
- States / cities
- Bakersfield, California • Tampa, Florida • Chicago, Illinois + 1 more
- Conditions
- Bladder Cancer, Recurrent Bladder Cancer, Non-muscle Invasive Bladder Cancer (NMIBC)
- Interventions
- Not listed
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- Tampa, Florida • Iowa City, Iowa • Chapel Hill, North Carolina + 3 more
- Conditions
- Bladder Cancer
- Interventions
- CG0070
- Biological
- Lead sponsor
- CG Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 17
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 13 more
- Conditions
- Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer
- Interventions
- Not listed
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 570 participants
- Timeline
- 2019 – 2029
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more
- Conditions
- Bladder Cancer
- Interventions
- Genistein, Sugar pill
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Bladder Cancer
- Interventions
- Qapzola, Placebo
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- High-Risk Non-Muscle-Invasive Bladder Cancer
- Interventions
- Cretostimogene Grenadenorepvec
- Drug
- Lead sponsor
- CG Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 79
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 70 more
- Conditions
- Non-muscle-invasive Bladder Cancer
- Interventions
- Gemcitabine, Docetaxel, Bacillus Calmette Guerin
- Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 870 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 229
- States / cities
- Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 163 more
- Conditions
- Non-muscle Invasive Bladder Cancer (NMIBC)
- Interventions
- ABI-009, Gemcitabine
- Drug
- Lead sponsor
- Aadi Bioscience, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 2
- States / cities
- New York, New York • Nashville, Tennessee
- Conditions
- Bladder Cancer
- Interventions
- HS-410, Placebo, BCG
- Biological
- Lead sponsor
- Heat Biologics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 19
- States / cities
- Los Angeles, California • Sherman Oaks, California • Torrance, California + 16 more
- Conditions
- Transitional Cell Carcinoma of Bladder, Superficial Bladder Cancer
- Interventions
- Hyperthermia System, Mitomycin C
- Device · Drug
- Lead sponsor
- Mark Dewhirst
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Durham, North Carolina